Real-time enrollment status for this advanced and/or metastatic solid tumors known to express b7-h3 clinical trial
Current Status
Recruiting
Checked: October 2, 2026 at 1:05 AM UTC
| NCT Number | NCT07807241 |
| Recruiting Status | Recruiting |
| Condition | Advanced and/or Metastatic Solid Tumors Known to Express B7-H3 |
| Phase | PHASE1 |
| Target Enrollment | 120 participants |
| Active Locations | 4 sites in the US |
| Sponsor | Myricx Pharma Limited |
| Last Updated on CT.gov | September 8, 2026 (3 weeks ago) |
As of October 2, 2026: Clinical trial NCT07807241 is currently recruiting participants. This phase1 study for advanced and/or metastatic solid tumors known to express b7-h3 is actively seeking new participants at 4 locations across the United States. The study is sponsored by Myricx Pharma Limited. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07807241 is actively recruiting participants as of October 2, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 4 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07807241 was last updated 3 weeks ago (September 8, 2026). HelloStudys verifies this status automatically.